Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury in the Emergency Department (BRAVA): A Multicenter Study Evaluating Urinary TIMP-2/IGFBP7.,Annals of Laboratory Medicine

当前位置： X-MOL 学术 › Ann. Lab. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury in the Emergency Department (BRAVA): A Multicenter Study Evaluating Urinary TIMP-2/IGFBP7.
Annals of Laboratory Medicine ( IF 4.0 ) Pub Date : 2021-10-13 , DOI: 10.3343/alm.2022.42.2.178
Hyun Suk Yang ₁ , Mina Hur ₂ , Kyeong Ryong Lee ₃ , Hanah Kim ₂ , Hahn Young Kim ₄ , Jong Won Kim ₃ , Mui Teng Chua ₅ , Win Sen Kuan ₅ , Horng Ruey Chua ₆ , Chagriya Kitiyakara ₇ , Phatthranit Phattharapornjaroen ₈ , Anchalee Chittamma ₉ , Thiyapha Werayachankul _{10,

11} , Urmila Anandh ₁₂ , Sanjeeva Herath ₁₃ , Zoltan Endre ₁₃ , Andrea Rita Horvath ₁₄ , Paola Antonini ₁₅ , Salvatore Di Somma _{15,

16} ,

Affiliation

Department of Cardiovascular Medicine, Konkuk University School of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Department of Emergency Medicine, Konkuk University School of Medicine, Seoul, Korea.
Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
Department of Emergency Medicine, Division of Nephrology, National University Health System, Singapore.
Department of Medicine, National University Hospital, National University Health System, Singapore.
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Emergency Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Section of Translational Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Department of Section of Pharmaceutical Care, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand.
Department of Nephrology, Yashoda Hospital, Secunderabad, India.
Department of Nephrology, Prince of Wales Hospital, Sydney, Australia.
New South Wales Health Pathology, Department of Chemical Pathology, Prince of Wales Hospital, Sydney, Australia.
GREAT Network Italy Rome, Italy.
Department of Medical-Surgery Sciences and Translational Medicine, University of Rome La Sapienza, Rome, Italy.

Urine tissue inhibitor of metalloproteinases-2/insulin-like growth factor-binding protein 7 (TIMP-2/IGFBP7) (NephroCheck, Ortho Clinical Diagnostics, Raritan, NJ, USA) is a US Food and Drug Administration-approved biomarker for risk assessment of acute kidney injury (AKI) in critically ill adult patients in intensive care units; however, its clinical impact in the emergency department (ED) remains unproven. We evaluated the utility of NephroCheck for predicting AKI development and short-term mortality in the ED.

中文翻译：

在急诊科 (BRAVA) 验证急性肾损伤患者的生物标志物纳入或排除：一项评估尿液 TIMP-2/IGFBP7 的多中心研究。

金属蛋白酶-2/胰岛素样生长因子结合蛋白 7 的尿组织抑制剂 (TIMP-2/IGFBP7) (NephroCheck, Ortho Clinical Diagnostics, Raritan, NJ, USA) 是美国食品和药物管理局批准的用于风险评估的生物标志物重症监护病房重症成年患者的急性肾损伤（AKI）；然而，它在急诊科 (ED) 中的临床影响仍未得到证实。我们评估了 NephroCheck 在预测急诊室 AKI 发展和短期死亡率方面的效用。

更新日期：2021-10-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11